Addressees
Registrant(s) of 115_JS_Chlorhexidine x 2 HCl as listed in Appendix 3 of this decision

Date of submission of the dossier subject to this decision
21/02/2022

Registered substance subject to this decision ("the Substance")
Substance name: Chlorhexidine dihydrochloride
EC number: 223-026-6

Decision number: Please refer to the REACH-IT message which delivered this communication (in format CCH-D-XXXXXXXXXX-XX-XX/F)

DECISION ON A COMPLIANCE CHECK

Under Article 41 of Regulation (EC) No 1907/2006 (REACH), you must submit the information listed below, by the deadline of 25 July 2024.

Requested information must be generated using the Substance unless otherwise specified.

Information required from all the Registrants subject to Annex VII of REACH

1. In vitro gene mutation study in mammalian cells (triggered at Annex VII, test method: OECD TG 476 or TG 490)

Information required depends on your tonnage band

You must provide the information listed above for all REACH Annexes applicable to you in accordance with Articles 10(a) and 12(1) of REACH. The addressees of the decision and their corresponding information requirements based on registered tonnage band are listed in Appendix 3.

You are only required to share the costs of information that you must submit to fulfil your information requirements.

How to comply with your information requirements

To comply with your information requirements, you must submit the information requested by this decision in an updated registration dossier by the deadline indicated above. You must also update the chemical safety report, where relevant, including any changes to classification and labelling, based on the newly generated information.

You must follow the general requirements for testing and reporting new tests under REACH, see Appendix 4.

Appeal

This decision, when adopted under Article 51 of REACH, may be appealed to the Board of Appeal of ECHA within three months of its notification to you. Please refer to

**Failure to comply**

If you do not comply with the information required by this decision by the deadline indicated above, ECHA will notify the enforcement authorities of your Member State.

Authorised\(^1\) under the authority of Mike Rasenberg, Director of Hazard Assessment

Appendix 1: Reasons for the decision  
Appendix 2: Procedure  
Appendix 3: Addressees of the decision and their individual information requirements  
Appendix 4: Conducting and reporting new tests under REACH

---

\(^1\) As this is an electronic document, it is not physically signed. This communication has been approved according to ECHA’s internal decision-approval process.
Appendix 1: Reasons for the decision

Contents

Reasons related to the information under Annex VII of REACH...................... 4

1. In vitro gene mutation study in mammalian cells ........................................... 4

References ........................................................................................................... 5
Reasons related to the information under Annex VII of REACH

1. **In vitro gene mutation study in mammalian cells**

An in vitro gene mutation study in bacteria is an information requirement under Annex VII, Section 8.4.1.

If the in vitro gene mutation test in bacteria is inapplicable to the Substance, an in vitro gene mutation study is necessary and appropriate to fulfill this information requirement and is to be conducted in mammalian cells.

According to the Guidance on IRs and CSA, Section R.7.7.6.3, and paragraph 6. of OECD TG 471, the in vitro gene mutation test in bacteria is inapplicable for the evaluation of certain classes of chemicals, for example highly bactericidal substances. In such cases of significant toxicity to bacteria, gene mutation tests in mammalian cells are recommended.

You have provided an in vitro gene mutation study in bacteria (2002) with the Substance (study i). You indicate that the study showed pronounced cytotoxicity starting from 1 µg/plate for the strains S. typhimurium TA 1535, TA 1537, TA 98 and TA 100. Since cytotoxicity occurred at such a low dose, the Substance appears significantly toxic to bacteria and, as indicated above, an in vitro gene mutation test in bacteria is not applicable.

Therefore, study (i) cannot fulfill the information requirement and an *in vitro* gene mutation study in mammalian cells is required.

1.1. **Information provided and its assessment**

You have provided no information on in vitro gene mutation in mammalian cells with the Substance.

On this basis, the information requirement is not fulfilled.

1.2. **Specification of the study design**

To fulfill the information requirement for the Substance, either the in vitro mammalian cell gene mutation tests using the hpmt and xprt genes (OECD TG 476) or the thymidine kinase gene (OECD TG 490) are considered suitable.
References

The following documents may have been cited in the decision.

**Guidance on information requirements and chemical safety assessment (Guidance on IRs & CSA)**
- Chapter R.6 QSARs, read-across and grouping; ECHA (2008).
- Appendix to Chapter R.6 for nanoforms; ECHA (2019).
- Chapter R.7a Endpoint specific guidance, Sections R.7.1 – R.7.7; ECHA (2017).
- Appendix to Chapter R.7a for nanomaterials; ECHA (2017).
- Chapter R.7b Endpoint specific guidance, Sections R.7.8 – R.7.9; ECHA (2017).
- Appendix to Chapter R.7b for nanomaterials; ECHA (2017).
- Chapter R.7c Endpoint specific guidance, Sections R.7.10 – R.7.13; (ECHA 2017).
- Appendix to Chapter R.7a for nanomaterials; ECHA (2017).
- Chapter R.16 Environmental exposure assessment; ECHA (2016).


**Read-across assessment framework (RAAF)**
- RAAF, 2017 Read-across assessment framework (RAAF), ECHA (2017)


**OECD Guidance documents (OECD GDs)**
- OECD GD 23 Guidance document on aquatic toxicity testing of difficult substances and mixtures; No. 23 in the OECD series on testing and assessment, OECD (2019).
- OECD GD 29 Guidance document on transformation/dissolution of metals and metal compounds in aqueous media; No. 29 in the OECD series on testing and assessment, OECD (2002).
Appendix 2: Procedure

This decision does not prevent ECHA from initiating further compliance checks at a later stage on the registrations present.

ECHA followed the procedure detailed in Articles 50 and 51 of REACH.

The compliance check was initiated on 16 November 2021.

ECHA notified you of the draft decision and invited you to provide comments.

ECHA did not receive any comments within the commenting period.

ECHA notified the draft decision to the competent authorities of the Member States for proposals for amendment.

As no amendments were proposed, ECHA adopted the decision under Article 51(3) of REACH.

The deadline of the decision is set based on standard practice for carrying out OECD TG tests. It has been exceptionally extended by 6 months from the standard deadline granted by ECHA to take into account currently longer lead times in contract research organisations.
Appendix 3: Addressees of this decision and their corresponding information requirements

In accordance with Articles 10(a) and 12(1) of REACH, the information requirements for individual registrations are defined as follows:

- the information specified in Annex VII to REACH, for registration at 1-10 tonnes per year (tpa), or as a transported isolated intermediate in quantity above 1000 tpa;
- the information specified in Annexes VII and VIII to REACH, for registration at 10-100 tpa;
- the information specified in Annexes VII, VIII and IX to REACH, for registration at 100-1000 tpa;
- the information specified in Annexes VII to X to REACH, for registration at more than 1000 tpa.

<table>
<thead>
<tr>
<th>Registrant Name</th>
<th>Registration number</th>
<th>Highest REACH Annex applicable to you</th>
</tr>
</thead>
<tbody>
<tr>
<td>xxxxxxxxxxxxxxxx</td>
<td>xxxxxxxxxxxxxxxxx</td>
<td>xxx xxx</td>
</tr>
<tr>
<td>xxxxxxxxxxxxxxxx</td>
<td>xxxxxxxxxxxxxxxxx</td>
<td>xxx xxx</td>
</tr>
<tr>
<td>xxxxxxxxxxxxxxxx</td>
<td>xxxxxxxxxxxxxxxxx</td>
<td>xxx xxx</td>
</tr>
</tbody>
</table>

Where applicable, the name of a third party representative (TPR) may be displayed in the list of recipients whereas ECHA will send the decision to the actual registrant.
Appendix 4: Conducting and reporting new tests for REACH purposes

1. Requirements when conducting and reporting new tests for REACH purposes

1.1. Test methods, GLP requirements and reporting

(1) Under Article 13(3) of REACH, all new data generated as a result of this decision must be conducted according to the test methods laid down in a European Commission Regulation or to international test methods recognised by the Commission or ECHA as being appropriate.

(2) Under Article 13(4) of REACH, ecotoxicological and toxicological tests and analyses must be carried out according to the GLP principles (Directive 2004/10/EC) or other international standards recognised by the Commission or ECHA.

(3) Under Article 10(a)(vi) and (vii) of REACH, all new data generated as a result of this decision must be reported as study summaries, or as robust study summaries, if required under Annex I of REACH. See ECHA Practical Guide on How to report robust study summaries.

(4) Under the introductory part of Annexes VII/VIII/IX/X to REACH, where a test method offers flexibility in the study design, for example in relation to the choice of dose levels or concentrations, the chosen study design must ensure that the data generated are adequate for hazard identification and risk assessment.

1.2. Test material

Before generating new data, you must agree within the joint submission on the chemical composition of the material to be tested (Test Material) which must be relevant for all the registrants of the Substance.

(1) Selection of the Test material(s)

The Test Material used to generate the new data must be selected taking into account the following:

- the variation in compositions reported by all members of the joint submission,
- the boundary composition(s) of the Substance,
- the impact of each constituent/impurity on the test results for the endpoint to be assessed. For example, if a constituent/impurity of the Substance is known to have an impact on (eco)toxicity, the selected Test Material must contain that constituent/impurity.

(2) Information on the Test Material needed in the updated dossier

- You must report the composition of the Test Material selected for each study, under the “Test material information” section, for each respective endpoint study record in IUCLID.
- The reported composition must include all constituents of each Test Material and their concentration values and other parameters relevant for the property to be tested.

This information is needed to assess whether the Test Material is relevant for the Substance and whether it is suitable for use by all members of the joint submission.

Technical instructions on how to report the above is available in the manual on How to prepare registration and PPORD dossiers.

---

3 https://echa.europa.eu/manuals